2021
Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application
Buono FD, Lalloo C, Larkin K, Zempsky WT, Ball S, Grau LE, Pham Q, Stinson J. Innovation in the treatment of persistent pain in adults with Neurofibromatosis Type 1 (NF1): Implementation of the iCanCope mobile application. Contemporary Clinical Trials Communications 2021, 25: 100883. PMID: 35036627, PMCID: PMC8743203, DOI: 10.1016/j.conctc.2021.100883.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain symptomsNF1 populationType 1Chronic pain symptomsSelf-management treatmentPersistent painTreatment satisfactionTreatment optionsControl studySix weeksPainPsychometric evaluationContingency managementInitial effectivenessGenetic disordersThird groupSymptomsAdultsTreatmentPopulationDifferent populationsGroupParticipants' experiencesGreater reach
2016
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence
Carroll KM, Nich C, Petry NM, Eagan DA, Shi JM, Ball SA. A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. Drug And Alcohol Dependence 2016, 160: 135-142. PMID: 26817621, PMCID: PMC4767616, DOI: 10.1016/j.drugalcdep.2015.12.036.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyCocaine outcomesCocaine dependenceCombination of CMDouble-blind clinical trialBehavioral therapyCommunity-based outpatient clinicsUrine sample testingBlind clinical trialSustained treatment effectContingency managementDSM-IV criteriaRandomized factorial trialCurrent cocaine dependenceWeekly individual sessionsCocaine use disorderSecondary outcomesPrimary outcomeYear followOutpatient clinicAddition of disulfiramClinical trialsUse disordersCBT treatmentFactorial trial
2010
Cost evaluation of evidence-based treatments.
Sindelar JL, Ball SA. Cost evaluation of evidence-based treatments. Addiction Science & Clinical Practice 2010, 5: 44-51. PMID: 22002453, PMCID: PMC3120119.Peer-Reviewed Original Research
2008
Serious Adverse Events in Randomized Psychosocial Treatment Studies: Safety or Arbitrary Edicts?
Petry NM, Roll JM, Rounsaville BJ, Ball SA, Stitzer M, Peirce JM, Blaine J, Kirby KC, McCarty D, Carroll KM. Serious Adverse Events in Randomized Psychosocial Treatment Studies: Safety or Arbitrary Edicts? Journal Of Consulting And Clinical Psychology 2008, 76: 1076-1082. PMID: 19045975, PMCID: PMC2756150, DOI: 10.1037/a0013679.Peer-Reviewed Original ResearchConceptsSerious adverse eventsAdverse eventsStandard careDrug Abuse Clinical Trials NetworkMore (95% CI 4 to 167 more) serious adverse eventsSAE incidence rateClinical Trials NetworkPsychosocial treatment studiesPsychosocial intervention studiesPercent of participantsPsychosocial trialsIncidence ratePharmaceutical trialsTherapy trialsIntervention studiesTreatment studiesTrials NetworkHuman subjects protection policiesSubstance-abusing participantsContingency managementMotivational enhancementNational InstituteTrialsSignificant differencesCare
2001
Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement. JAMA Psychiatry 2001, 58: 755-761. PMID: 11483141, PMCID: PMC3651594, DOI: 10.1001/archpsyc.58.8.755.Peer-Reviewed Original ResearchConceptsDrug-free urine specimensNaltrexone treatmentFamily counseling sessionsContingency managementOpioid dependenceTreatment retentionUrine specimensBehavioral therapyOpioid-dependent individualsCounseling sessionsDrug use outcomesSubstance abuse outcomesNaltrexone complianceNaltrexone therapyOpioid useAvailable pharmacotherapiesMedication complianceSpecific pharmacotherapySignificant improvementTherapyUse outcomesAbuse outcomesPrincipal outcomePharmacotherapyTreatment